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Abstract
Obesity is a multifactorial disease caused by the interaction between genotype and environment, and it is considered to be
a type of addictive alteration. The A1 allele of the DRD2/ANKK1-TaqIA gene has been associated with addictive disorders,
with obesity and with the performance in executive functions. The 7 repeat allele of the DRD4 gene has likewise been
associated with the performance in executive functions, as well as with addictive behaviors and impulsivity. Participants
were included in the obesity group (N = 42) if their body mass index (BMI) was equal to or above 30, and in the lean group
(N = 42) if their BMI was below 25. The DRD2/ANKK1-TaqIA and DRD4 VNTR polymorphisms were obtained. All subjects
underwent neuropsychological assessment. Eating behavior traits were evaluated. The ‘DRD2/ANKK1-TaqIA A1-allele status’
had a significant effect on almost all the executive variables, but no significant ‘DRD4 7R-allele status’ effects were observed
for any of the executive variables analyzed. There was a significant ‘group’ x ‘DRD2/ANKK1-TaqIA A1-allele status’ interaction
effect on LN and ‘group’ x ‘DRD4 7R-allele status’ interaction effect on TMT B-A score. Being obese and a carrier of the A1
allele of DRD2/ANKK1-TaqIA or the 7R allele of DRD4 VNTR polymorphisms could confer a weakness as regards the
performance of executive functions.
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Introduction
Obesity is a chronic multifactorial disease caused by the
interaction between genotype and environment, and it is
considered the second cause of premature and avoidable mortality,
after tobacco [1,2]. It has also been suggested as a possible risk
factor for neurodegenerative diseases [3,4] and has been associated
with an increased rate of psychiatric disease, such as depression
[5]. At the same time, obesity can be considered as a type of
addictive disorder involving an alteration of normal cerebral
functioning, one that is characterized by compulsive food intake
and an inability to limit ingestion [6]. Both palatable food and
drugs appear to activate the same mesolimbic dopamine reward
system in the human brain and animal models [7–9]. Thus,
dopamine genes may influence the relationship between obesity,
the sensitivity to reinforcement and decision making.
DRD2 is a gene encoding the D2 dopamine receptor, which is
mainly expressed in the striatum [10–13]. The DRD2/ANKK1-
TaqIA polymorphism is located, 10 kb downstream from the
DRD2 gene, in the exon 8 of the adjacent gene, denoted the
ankyrin repeat and kinase domain containing 1 (ANKK1) [14].
The DRD2/ANKK1-TaqIA polymorphism modulates the density
of D2 receptors. Carriers of the A1 allele have shown up to 30%
reduced D2 receptor density compared to homozygous A2 allele
carriers [11,13,15,16]. This reduction is particularly prominent in
ventral parts of the caudate and putamen. Reduced glucose
metabolism is also observed in carriers of the A1 allele, not only in
the striatum but also in remote areas such as the ventral and
medial prefrontal cortex [17].
The A1 allele of the DRD2/ANKK1-TaqIA gene has been
associated with both addictive disorders [18–20] and obesity
[21,22]. The A1 allelic prevalence has been reported to be
significantly higher in obese individuals than in lean controls [23–
25]. Moreover, obese subjects, relative to lean ones, have fewer D2
receptors in the striatum [22,26,27].
Further to these findings, imaging studies have reported that the
reductions in D2 receptors are associated with decreased
metabolism in prefrontal cortical regions in obese subjects [28],
in whom an inverse relationship between body mass index (BMI)
and D2 receptors has also been described; specifically, those
individuals with the lowest D2 values had the largest BMI [22].
Lower prefrontal metabolic activity has also been reported in
healthy adults with the highest BMI [28,29].
PLoS ONE | www.plosone.org 1 July 2012 | Volume 7 | Issue 7 | e41482
There are controversial results regarding the relationship
between DRD2/ANKK1-TaqIA polymorphisms and cognitive
processes. Berman and Noble [30] reported significantly reduced
visuo-spatial performance in healthy children with the A1 allele
compared with A1 non-carriers. An association between posses-
sion of the A1 allele of the DRD2/ANKK1-TaqIA polymorphism
and intelligence has also been reported, but in the opposite
direction. Carriers of the A1/A1 genotype in an adult female
sample had a significantly higher IQ than did carriers of the A2/
A2 genotype [31]. In a sample of memory-impaired subjects, those
Table 1. Demographic and clinic characteristics in obese subjects.
Age Sex/Ethnia Weight (Kg) Height (m) BMI (kg/m2) SAP DAP TGL Total CHO Gly
1 32 F/C 87.00 1.61 33.56 96 56.50 0.64 3.93 4.25
2 30 F/H 137.00 1.62 52.20 119 73 2.22 4.89 4.94
3 37 F/C 83.50 1.64 31.05 101.5 73 0.91 4.02 4.47
4 29 M/C 141.60 1.83 42.28 127 74.5 1.40 5.17 4.86
5 36 F/C 127.00 1.59 50.24 117 71 1.83 4.27 6.19
6 37 F/C 122.80 1.65 45.11 110 74.5 1.04 3.77 4.47
7 36 M/C 96.60 1.67 34.64 101 61 1.09 4.08 4.79
8 39 F/C 80.00 1.60 31.25 126 84 1.21 4.65 5.29
9 33 F/C 104.50 1.68 37.03 113 81.5 0.94 3.49 4.67
10 21 F/C 106.00 1.60 41.41 123 80 1.91 4.68 4.00
11 37 F/C 91.50 1.69 32.04 102 73 1.27 5.04 4.56
12 34 M/C 117.00 1.80 36.11 120 80 1.50 5.51 4.74
13 39 M/H 96.00 1.62 36.58 128 53 1.25 5.08 4.82
14 34 F/C 79.50 1.54 33.52 109.5 69.5 0.89 3.83 4.05
15 37 F/C 83.00 1.65 30.49 99.5 61.5 1.48 4.54 4.78
16 39 M/C 118.70 1.67 42.56 127 82 .48 5.34 5.08
17 35 F/C 79.40 1.62 30.25 110.5 65 0.85 3.68 4.18
18 36 F/C 94.00 1.57 38.14 120 69 0.97 4.45 4.94
19 38 M/C 115.50 1.81 35.26 115 73 1.59 4.39 4.40
20 26 M/C 147.00 1.72 49.69 111 72 1.33 3.76 5.09
21 30 F/C 113.00 1.78 35.66 112 72 1.12 4.22 4.02
22 38 F/C 92.40 1.54 38.96 104.5 60 2.27 4.98 6.70
23 25 M/C 194.00 1.72 65.58 129 70 2.64 4.58 4.66
24 36 F/C 100.00 1.62 38.10 110 80 .65 4.34 5.15
25 21 F/C 142.50 1.71 48.73 120 69 1.57 3.92 5.67
26 24 F/C 98.00 1.68 34.72 106.5 66.5 0.99 3.61 4.10
27 19 F/C 129.00 1.69 45.17 111 73 1.25 4.54 4.68
28 35 F/C 87.00 1.61 33.56 100 68 0.49 4.53 4.40
29 20 F/C 118.00 1.68 41.81 115 80 0.61 4.06 4.62
30 22 F/C 84.00 1.61 32.43 115 71.5 1.15 4.06 4.34
31 27 M/C 85.00 1.68 30.10 111 78 1.55 4.79 4.24
32 35 F/C 76.00 1.55 31.63 123.5 80 1.50 4.63 4.57
33 38 M/C 105.50 1.78 33.30 138 81 2.06 5.93 4.34
34 33 M/C 97.00 1.71 33.17 134.5 87 1.34 4.76 4.79
35 37 F/C 112.80 1.73 37.69 132.5 85 1.12 4.61 4.12
36 37 F/C 127.50 1.62 48.58 136 90 1.32 5.23 4.53
37 30 M/H 129.00 1.78 40.71 131 81. 2.57 7.16 4.90
38 35 M/C 138.00 1.77 44.05 130 80 1.56 4.52 4.20
39 31 M/C 100.00 1.66 36.29 136.5 87.5 1.69 4.18 4.77
40 30 F/C 104.50 1.75 34.12 133 82.5 2.01 4.00 5.65
41 35 F/C 87.00 1.62 33.15 131.5 75.5 1.16 4.42 4.36
42 34 M/C 109.00 1.69 38.16 135 86 2.85 5.35 5.36
C = Caucasian; H = Hispanic; SAP = Systolic arterial pressure; DAP = Diastolic arterial pressure; TGL = blood triglycerides (mmol/l); CHO = blood cholesterol (mmol/l);
Gly = Glycemia (mmol/l).
doi:10.1371/journal.pone.0041482.t001
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homozygous for the A2 allele exhibited worse performance in
verbal memory and general cognitive ability than did those
subjects bearing the A1 allele [32].
As regards frontal functions some studies in healthy adult
samples have found that carriers of the A1 allele (who have a lower
density of D2 receptors) display better behavioural flexibility than
do A1 non-carriers [33,34]. Other authors have reported that A1
carriers have difficulty in learning from negative feedback in a
reinforcement learning task [35] and are less efficient at learning to
avoid actions that have negative consequences [36], although
Table 2. Demographic and clinic characteristics in normal-weight subjects.
Age Sex/Ethnia Weight (Kg) Height (m) BMI (kg/m2) SAP DAP TGL Total CHO Gly
1 32 F/C 44.5 1.48 20.32 116.5 66 0.65 4.47 4.42
2 25 F/C 47.5 1.63 17.88 123 76 0.53 3.68 4.98
3 27 F/C 51 1.63 19.2 104.5 64 0.7 4.05 4.37
4 30 F/C 50 1.6 19.53 110 70 0.45 3.93 4.34
5 20 F/C 56 1.62 21.34 102.5 66.5 1.01 4.87 4.22
6 22 F/H 56.9 1.6 22.23 98.5 59.5 0.78 5.24 4.69
7 37 F/C 58 1.72 19.61 125.5 77.5 0.54 3.7 4.25
8 20 M/C 80.6 1.84 23.81 120 75 0.99 4.08 5.06
9 19 F/C 52 1.64 19.33 101 61 0.48 4.27 4.38
10 19 M/C 67 1.64 24.91 100 60 0.54 4.75 4.45
11 20 F/C 62 1.64 23.05 102 67 1.05 4.56 4.43
12 19 F/C 49 1.5 21.78 132 74 0.78 3.98 4.6
13 25 M/C 65.9 1.75 21.52 114 58 0.64 3.43 4.38
14 35 F/C 56 1.61 21.6 117.5 80 0.64 4.69 4.85
15 40 M/C 68.9 1.71 23.56 100 71 1.02 4.31 4.64
16 36 F/C 54.8 1.66 19.89 95.5 64 0.89 4.39 4.44
17 35 F/C 60 1.56 24.65 131 76 0.5 4.59 4.55
18 19 F/C 63.4 1.74 20.94 108 66 0.56 3.21 4.66
19 25 M/C 78 1.84 23.04 109 65 0.66 3.82 4.29
20 20 F/C 52.5 1.54 22.14 108 67.5 1.51 4.36 4.51
21 33 F/C 50 1.64 18.59 106 72 1.12 3.77 4.22
22 33 F/C 59 1.54 24.88 99.5 63.5 1.87 4.65 4.76
23 31 M/C 82 1.91 22.48 115.5 66 0.68 3.74 4.64
24 40 M/H 51.8 1.55 21.56 101 62 0.42 3.37 4.82
25 30 M/C 67.7 1.86 19.57 123 60 1.23 4.15 4.3
26 36 F/C 59 1.54 24.88 110 71 0.58 4.96 4.53
27 34 M/H 60 1.64 22.31 104.5 64 1.3 6.29 5.09
28 38 F/C 58.5 1.58 23.43 110 77 0.81 4.86 4.38
29 32 F/C 68.5 1.78 21.62 109.5 80 0.65 4.26 4.25
30 36 F/C 55.2 1.58 22.11 121 65 0.68 6.06 4.15
31 39 F/C 55.1 1.57 22.35 116 60.5 0.42 4.37 4.43
32 36 M/C 64.5 1.75 21.06 119.5 75 0.64 4.26 5.65
33 39 F/C 61.3 1.57 24.87 117 68 1.82 4.51 4.35
34 34 F/C 59.7 1.66 21.8 107.5 69 0.61 4.74 3.86
35 30 F/C 48.2 1.59 19.07 98 63 1.04 4.14 4.06
36 31 F/C 72.8 1.72 24.61 100 60 0.63 4.39 4.21
37 31 F/C 66.4 1.74 21.93 118.5 69 0.9 4.96 4.68
38 24 M/C 93 1.93 24.97 114 67 0.51 4.12 4.85
39 24 M/C 79.8 1.84 23.57 120 70 0.55 3.89 5.04
40 39 F/C 62 1.6 24.23 110 69 0.46 4.25 5.13
41 30 M/C 68.5 1.69 23.95 100 68 0.76 5.23 4.87
42 21 F/C 69.5 1.75 22.69 117 86 0.99 4.46 4.9
C = Caucasian; H = Hispanic; SAP = Systolic arterial pressure; DAP = Diastolic arterial pressure; TGL = blood triglycerides (mmol/l); CHO = blood cholesterol (mmol/l);
Gly = Glycemia (mmol/l).
doi:10.1371/journal.pone.0041482.t002
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some investigators have failed to find an association between
frontal function and the DRD2/ANKK1-TaqIA polymorphism
[37].
Another gene encoding dopamine receptors is DRD4, which is
highly expressed in the prefrontal cortex and other brain regions
that are involved in the reward circuits that mediate the
reinforcing properties of food, such as the hippocampus, amygdala
and hypothalamus [38,39]. The most widely studied polymor-
phism of the DRD4 gene is located in the third exon and contains
a 48 base-pair, variable number of tandem repeats (48-bp VNTR).
Nine alleles of the DRD4 48-bp VNTR have been identified
worldwide, with the number of repeats ranging between 2 and 10.
The 4- and 7-repeat (7R and 4R) alleles are the most common
globally [40]. The number of 48-bp repeats has been hypothesized
to affect the transmitted signal in the postsynaptic neuron.
Individuals with at least one allele containing seven or more
repeats show both reduced binding affinities and receptor densities
for dopamine neurotransmission [41].
Table 3. Comparison between obese and control subjects in
demographics, neuropsychological and questionnaire scores.
Obese
(N=42)
Lean
(N=42) Statistic p
x2
Gender (F/M) 28/14 29/13 0.05 0.815
Mean (SD) Mean (SD) T
Age 31.81 (6.51) 29.67 (6.97) 1.45 0.149
Education (years) 12.26 (2.87) 13.55 (2.40) 22.22 0.029
BMI 38.30 (7.59) 22.07 (1.97) 31.77 ,0.001
HADS1 1.43 (1.71) 1.24 (1.54) 0.53 0.594
Vocabulary WAIS (scalar
score)
11.26 (2.19) 11.24 (1.88) 0.05 0.958
LN1 11.79 (2.64) 11.12 (1.80) 1.35 0.179
SDMT1 54.26 (10.47) 57.21 (11.18) 21.24 0.215
TMT B (s) 65.76 (28.89) 70.24 (24.25) 20.76 0.444
TMT B-A (s) 36.98 (24.18) 41.90 (21.24) 20.99 0.324
COWAT1 36.69 (10.91) 37.64 (10.98) 20.39 0.691
Stroop interference 5.24 (6.35) 3.92 (7.98) 0.84 0.403
WCST perseverative errors115.36 (10.64) 15,76 (11.80) 20.16 0.869
BITE symptoms1 9.12 (6.41) 2.71 (2.87) 5.91 ,0.001
3FEQ dietary restraint1 13.66 (4.04) 10.70 (3.66) 3.51 0.001
3FEQ disinhibition1 21 (6.83) 13.57 (4.09) 6.05 ,0.001
3FEQ hunger1 7.50 (2.59) 4.81 (2.37) 4.96 ,0.001
1is for raw score.
F = female; M = male; BMI = body mass index; HADS = Hamilton Anxiety and
Depression Scale; LN = Letters and Numbers (WAIS III); SDMT = Symbol Digit
Modalities Test; TMT = Trail making Test; WCST = Wisconsin Card Sorting Test;
BITE = Bulimic lnvestigatory Test Edinburgh; 3FEQ = 3-factor Eating
Questionnaire.
doi:10.1371/journal.pone.0041482.t003
Table 4. Frequencies of DRD2/ANKK1 alleles and genotypes
in obese and control subjects.
N (%)
Obese (N=42) Control (N=42)
Allele
A1 10 (12) 13 (15.5)
A2 74 (88) 71 (84.5)
Genotype
A1A1 2 (4.8) 1 (2.4)
A1A2 6 (14.3) 11 (26.2)
A2A2 34 (81) 30 (71.4)
doi:10.1371/journal.pone.0041482.t004
Table 5. Frequencies of DRD4 exon 3 VNTR alleles and
genotypes in obese and control subjects.
N (%)
Obese (N=42) Control (N=42)
Allele (%)
2 7 (8.3) 11 (13.1)
3 3 (3.6) 6 (7.2)
4 59 (70.2) 58 (69)
5 3 (3.6) 1 (1.2)
7 12 (14.3) 7 (8.3)
8 0 1 (1.2)
Total 84 (100) 84 (100)
Genotype (%)
2,2 1 (2.4) 2 (4.8)
2,3 0 1 (2.4)
2,4 5 (11.9) 5 (11.9)
2,7 0 1 (2.4)
3,3 0 1 (2.4)
3,4 3 (7.1) 3 (7.1)
4,4 20 (47.6) 23 (54.8)
4,5 3 (7.1) 1 (2.4)
4,7 8 (19) 3 (7.1)
7,7 2 (4.8) 1 (2.4)
7,8 0 1 (2.4)
Total 42 (100) 42 (100)
doi:10.1371/journal.pone.0041482.t005
Table 6. Frequencies of ‘DRD2/ANKK1-TaqIA A1-allele status’
and ‘DRD4 VNTR 7R-allele status’ in obese and control
subjects.
Genotype Obese Control x2df
1 p
DRD2/ANKK1
A1(+) 8 (7 F) 12 (5 F) 1.051 0.22
A1(2) 34 (20 F) 30 (24 F)
DRD4 VNTR
7-R (+) 10 (4 F) 6 (3 F) 1.231 0.20
7-R (2) 32 (21 F) 36 (26 F)
The number of females in each group is given in parentheses.
1Comparison is for the ‘allele status’ frequency.
doi:10.1371/journal.pone.0041482.t006
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The DRD4 gene has been associated with addictive behaviours
[42] and with increased food intake in patients treated with D4
receptor-related antipsychotics [43]. The 7R allele has been linked
to attention deficit and hyperactivity disorder (ADHD) [44–46]
and to body weight gain in patients with seasonal affective disorder
[47]. The 7R allele has also been found to be associated with
impulsivity and lower levels of response inhibition in healthy
adults, both alone and in combination with other polymorphisms
in dopamine system genes, such as DRD2 [48,49].
Research into the link between DRD4 and cognitive functions
has also yielded mixed results. Some studies have reported
associations between being a carrier of 7R allele and impairment
on executive function tasks in healthy children [50], as well as in
children with ADHD [50–52]. However, Manor et al. [53]
reported just the opposite: their ADHD children with the DRD4
long repeats (6–8) performed better on attention than did those
bearing the DRD4 short repeats (2–5). In a recent study of healthy
adults, 7R allele carriers showed impaired reaction times
compared with non-carriers [54]. In addition, a recent experi-
mental study demonstrated impaired attentional performance in
animals with a genetically-induced reduction in DRD4 expression
[55]. Other studies, however, have shown no differences in
performance on different attentional domains for 7R carriers
among ADHD patients [44,51,53,56].
Since the DRD2 and DRD4 genes have been associated with
susceptibility to obesity and anomalous eating behaviour, and
given that polymorphisms of these genes seem to affect the
performance of executive functions, which appear to be altered in
obesity, it would seem logical to ask whether there is any
relationship between these polymorphisms and executive function
in obese subjects. No study to date has examined a possible effect
of DRD2/ANKK1-TaqIA and DRD4 VNTR polymorphisms on
executive performance in the obese population. However, it must
be taken into account that depression is the most frequent co-
morbidity of obesity [5] and is also associated with alteration of
executive functions [57]. What is more, depression has been
Table 7. Effect of ‘group’, ‘DRD2/ANKK1-TaqIA A1-allele status’ and their interactions with executive functions and eating
behavior.
Obese Control F Ef S ( 2)
A1 (+) (N=8) A1 (2) (N=34) A1 (+) (N=12) A1 (2) (N=30)
Mean (SD)/Range Mean (SD)/Range Mean (SD)/Range Mean (SD)/Range
LN1 9.87 (1.55)/7; 12 12.24 (2.65)/8; 16 11.00 (1.41)/9; 14 11.16 (1.94)/7; 15 Group = 0.010
Allele status= 6.33*
Interaction = 4.918*
0.00257
0.00200
SDMT1 49.12 (9.14)/36; 63 55.47 (10.51)/36; 77 53.50 (13.14)/34; 77 58.70 (10.16)/36; 77 Group = 1.72
Allele status= 3.98*
Interaction = 0.03
0.00170
TMT B (s) 91.87 (38.59)/50; 152 59.41 (22.69)/36; 136 78.25 (25.04)/47; 123 67.03 (23.58)/37; 140 Group = 0.00
Allele status= 8.50**
Interaction = 1.37
0.01107
TMT B-A (s) 56.87 (29.45)/31; 105 32.26 (20.57)/3; 107 43.58 (24.10)/21; 99 41.23 (20.38)/8; 99 Group = 0.011
Allele status= 3.57
Interaction = 2.18
COWAT1 34.25 (12.42)/19; 60 38.17 (10.17)/14; 66 37.50 (9.68)/18; 56 37.70 (11.61)/17; 59 Group = 0.16
Allele status= 0.08
Interaction = 0.05
Stroop interference 3.71 (6.28)/22.31; 17.03 5.36 (6.34)/25.80; 16.32 1.61 (6.67)/213.90; 10.12 4.84 (8.36)/221; 19 Group = 0.58
Allele status= 1.75
Interaction = 0.13
WCST perseverative
errors1
25.75 (10.66)/12; 44 12.97 (9.15)/4; 44 18.16 (12.39)/4; 44 14.80 (11.63)/4; 48 Group = 0.98
Allele status= 7.99**
Interaction = 2.72
0.03030
BITE symptoms1 14.50 (6.54)/6; 24 7.73 (5.78)/0; 24 2.75 (3.59)/0; 12 2.70 (2.58)/0; 8 Group = 45.03***
Allele status= 5.62*
Interaction = 5.49*
0.15788
0.01971
0.01923
3FEQ Dietary restraint115. 12 (5.93)/6; 23 13.27 (3.49)/6; 19 9.41 (2.99)/6; 16 11.21 (3.82)/5; 18 Group = 13.14**
Allele status= 0.13
Interaction = 2.17
0.01332
3FEQ Disinhibition1 26.25 (6.38)/17; 36 19.47 (6.52)/10; 35 13. 83 (5.40)/9; 25 13.46 (3.53)/8; 24 Group = 40.90***
Allele status= 4.40*
Interaction = 3.41
0.03970
0.00427
3FEQ Hunger1 9.50 (1.92)/7; 12 7.00 (2.52)/3; 12 5.08 (2.81)/3; 11 4.70 (2.21)/3; 12 Group = 25.934***
Allele status= 3.403
Interaction = 1.517
0.03621
Results are controlled for depression scores.
1raw score.
SD = Standard deviation; LN = Letters and Numbers (WAIS III); SDMT = Symbol Digit Modalities Test; TMT = Trail making Test; WCST = Wisconsin Card Sorting Test;
BITE = Bulimic lnvestigatory Test Edinburgh; 3FEQ = 3-factor Eating Questionnaire.
*p,0.05; **p,0.01; ***p,0.001; Ef S = effect size: 2 = 0.0099, small effect; 2 = 0.0588, medium effect; 2 = 0.1379, large effect.
doi:10.1371/journal.pone.0041482.t007
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shown to be a mediator between executive function and obesity
[58], and striatal dopamine levels are low in depressive subjects
[59]. For these reasons we should consider the levels of depression
as a control variable in the analysis of any relationship between
these polymorphisms and executive function in obese subjects.
Thus, the purpose of the present study was to assess the
association between two dopamine genes and executive function
and their potential interactions with obesity. The relationship
between these polymorphisms and eating behaviour variables was
also studied.
Materials and Methods
Participants were randomly selected from a population base of
1539 people living within the catchment area of three public
medical centres belonging to the Consorci Sanitari de Terrassa.
The recruitment process continued until two samples with similar
demographic features were obtained. Specifically, 816 potential
participants were contacted by telephone (see the Figure S1 for
detailed information on data inclusion) and 126 agreed to
participate in the study; of these, 16 individuals were excluded
(see criteria below) and 26 subsequently decided to leave the study.
The final sample therefore comprised 84 people, with an age range
of 19 to 40 years. Participants were included in the obesity group
(N = 42) if their body mass index (BMI) was equal to or above 30,
and in the lean group (N = 42) if their BMI was below 25.
Exclusion criteria were: a history of neurological or psychiatric
disorder, with the possible presence of anxiety or depression being
assessed via the Hospital Anxiety and Depression Scale (HADS)
[60], and the pathological use of alcohol and/or drugs being
evaluated with the Structured Clinical Interview for DSM-IV
(SCID-I) [61]; a history of any disorder that could be related to
obesity (e.g. thyroid dysfunctions); the presence of diabetes or
hypertension; BMI in the overweight range (i.e. 25–29.9); and the
presence of cognitive impairment. The study was approved by the
institutional ethics committee (Comissio´ de Bioe`tica de la
Universitat de Barcelona (CBUB); Institutional Review Board
IRB 00003099 Assurance number: FWA00004225; http://www.
ub.edu/recerca/comissiobioetica.htm) and the research was
conducted in accordance with the Helsinki Declaration. Written
informed consent was obtained from each participant prior to
taking part in the study. The demographic and clinical
characteristics of the obese and control groups are shown in
table 1 and table 2.
Genotyping
Venous blood was drawn from all subjects and genomic DNA
was extracted automatically by the MagNaPure Compact
Instrument (Roche Applied Science, Barcelona, Spain) according
to the manufacturer’s protocol. The DRD2/ANKK1 TaqIA
(rs1800497) and DRD4 VNTR (rs1805186) polymorphisms were
analysed as described below.
The DRD2/ANKK1-TaqIA polymorphism was amplified by
polymerase chain reaction (PCR) containing 100 ng of genomic
DNA from each subject, 0.5 mM each of forward (59-
GGCTGGCCAAGTTGTCTA-39) and reverse (59-
CCTTCCTGAGTGTCATCA-39) primers, 16 PCR buffer,
1 mM MgCl2, 200 mM of dNTPs and 2.5 units of BioTaq DNA
polymerase (Bioline, Ecogen, Barcelona, Spain). The PCR
Figure 1. ‘Group’ x ‘DRD2/ANKK1-TaqIA A1-allele status’ interaction effect on the LN score. Performance in LN is obtained by regressing
depression on the dependent variable, and then saving the standardized residual from this model.
doi:10.1371/journal.pone.0041482.g001
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programme was 95uC for 5 min followed by 35 cycles of 94uC for
30 s, 59uC for 30 s and 72uC for 1 min. The 302 bp PCR product
was digested with TaqaI enzyme (New England Biolabs, Izasa,
Barcelona, Spain) for 90 min at 65uC and visualized under
ultraviolet light on an 8% ethidium bromide acrylamide gel. The
DRD2-A2 allele was cleaved into two fragments of 176 and
126 bp, whereas the DRD2-A1 allele was not cleaved.
The DRD4 48-bp VNTR polymorphism was amplified by PCR
containing 100 ng genomic DNA, 0.5 mM of each primer (59-
GCGACTACGTGGTCTACTCG-39 as forward and 59-AG-
GACCCTCATGGCCTTG-39 as reverse), 16 PCR buffer,
1 mM MgCl2, 5% DMSO, 200 mM of dATP, dCTP and dTTP,
140 mM of dGTP, 60 mM of 7-deazaGTP and 2.5 units of BioTaq
DNA polymerase (Bioline). Cycling conditions were 35 cycles at
94uC for 30 s, 63uC for 30 s and 72uC for 1 min. Amplification
products were resolved by 5% acrylamide gel electrophoresis and
were subsequently stained with ethidium bromide and visualized
under ultraviolet light. Fragment sizes were determined by
comparison with molecular length standards. A 4-repeat PCR
product has a length of 475 bp. Genotyping was successful in all
participants. Each genotype was recoded as carrier versus non-
carrier of the allele of interest.
Neuropsychological Assessment
All subjects underwent neuropsychological assessment of
executive functions, this being based on the following tests.
Letter-Number Sequencing (LN) was used to assess processing
speed and verbal and visuo-spatial working memory (WM)
[62,63]. Visual scanning, tracking and motor speed were
assessed by the written part of Symbol Digit Modalities Test
(SDMT) [64]. Parts A and B of the Trail Making Test (TMT)
were administered to measure visual scanning, motor speed and
attention and mental flexibility [65]; a difference score (B-A)
that removes the speed element from the test evaluation was
calculated here [66]. The Controlled Oral Word Association
Test (COWAT) was used to evaluate verbal fluency [67]. This
measure has been shown to be sensitive to aspects of executive
functioning such as initiation and sustained effort. Here, the
number of words beginning with the letters F, A and S which
were recalled in 1 minute was recorded. The Stroop test
consists of three subtests: words, colours and colour words that
conflict with the colour in which they are presented. Here the
interference score was calculated as a measure of cognitive
inhibitory control [68]. The Wisconsin Card Sorting Test
(WCST) is a test of executive functioning that assesses cognitive
flexibility and set-shifting. The individual is asked to match
pictured designs based on rules that are not presented directly
but which must be inferred from feedback given about the
correctness of the matches; after a series of correct matches the
underlying rule is changed. Here the computerized 128-card
version of the WCST was used and the number of perseverative
errors was recorded [69].
Eating behaviour traits were assessed using the Three-Factor
Eating Questionnaire (3FEQ) [70] and the Bulimic Investigatory
Test, Edinburgh (BITE) [71]. The 3FEQ is a 51-item validated
questionnaire that assesses three factors (in the form of specific
subscales) that refer to cognitions and behaviours: dietary
restraint, disinhibition and hunger. Dietary restraint involves
Figure 2. ‘Group’ x ‘DRD2/ANKK1-TaqIA A1-allele status’ interaction effect on BITE symptoms. Scores in BITE symptoms are obtained by
regressing depression on the dependent variable, and then saving the standardized residual from this model.
doi:10.1371/journal.pone.0041482.g002
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the conscious control of food intake in order to control body
weight. Dietary disinhibition is characterized by an overcon-
sumption of foods in response to a variety of stimuli (e.g.
emotional stress) and is associated with a loss of control over
food intake. Hunger represents food intake in response to
feelings and perceptions of hunger. The BITE is a 33-item, self-
report questionnaire designed as an objective screening test to
identify subjects with bulimic symptoms and it consists of two
subscales: the symptoms scale (30 items), which determines the
seriousness of the symptoms, and the severity scale (3 items),
which offers a severity index. The score used in the present
study was that obtained from the symptoms scale, which
comprises items relating to symptoms such as bulimic behav-
iours and weight control strategies.
Statistical Analysis
Statistical analyses were performed by means of PASW
Statistics 18.0 (SPSS Inc, Chicago, IL, USA). The Kolmogorov-
Smirnov test was used to test whether all continuous variables
followed a normal distribution. Frequencies of polymorphisms
and alleles were calculated. Chi-square analysis tested for
goodness-of-fit to the Hardy-Weinberg equilibrium. The
Mann-Whitney U test was used to compare categorical variables
between the genetic groups, whereas the continuous variables
were compared via the Student’s t-test for independent samples.
Factorial ANCOVA was performed to determine the effect of
group (obesity), allele status (carrier vs. non carrier) and their
interaction on executive function and eating behaviour variables
controlling for confounding variables (score in HADS depression
questionnaire and sex). Given the low number of participants
who were simultaneously carriers of A1 (DRD2/ANKK1-
TaqIA) and 7R (DRD4 VNTR), we did not examine the
interaction between these two genes; instead, separate ANCO-
VAs were performed for each allele status (carrier vs non
carrier). Finally, the effect size was calculated according to the
value of eta squared (2). The interpretation of this statistic is as
follows: 2 = 0.0099, small effect; 2 = 0.0588, medium effect;
2 = 0.1379, large effect [72].
Table 8. Effect of ‘group’, ‘DRD4 7R-allele status’ and their interactions with executive functions and eating behavior.
Obese Control F Ef S ( 2)
7-R (+) (N=10) 7-R (2) (N=32) 7-R (+) (N=6) 7-R (2) (N=36)
Mean (SD)/Range Mean (SD)/Range Mean (SD)/Range Mean (SD)/Range
LN1 11.00 (2.05)/7; 13 11.65 (1.92)/8; 16 11.66 (2.33)/9; 15 11.02 (1.71)/7; 14 Group = 0.08
Allele status= 0.08
Interaction = 1.38
SDMT1 52.00 (11.87)/39; 77 54.96 (10.09)/36; 75 53.83 (9.84)/38; 65 57.77 (11.41)/34; 77 Group = 0.49
Allele status= 0.03
Interaction = 0.12
TMT B (s) 84.30 (40.87)/46; 152 59.75 (21.71)/36; 130 63.00 (16.00)/37; 84 71.44 (25.33)/41; 140 Group = 0.60
Allele status = 0.44
Interaction = 7.30**
0.00939
TMT B-A (s) 51.70 (35.51)/20; 107 32.34 (17.74)/3; 89 32.50 (13.03)/18; 53 43.47 (22.05)/8; 99 Group = 0.62
Allele status = 0.12
Interaction = 9.03**
0.02129
COWAT1 35.30 (5.39)/29; 44 38.09 (11.74)/14; 66 34.16 (14.53)/17; 59 38.22 (10.42)/18; 57 Group = 0.00
Allele status= 1.07
Interaction = 0.02
Stroop
interference
4.90 (6.23)/22.31; 15 5.10 (6.41)/25.80; 17.03 4.60 (7.94)/22.90; 19 3.80 (8.08)/221; 17.60 Group = 0.21
Allele status = 0.07
Interaction = 0.07
WCST
perseverative
errors1
18.70 (11.66)/7; 44 14.37 (10.24)/4; 44 17.50 (16.09)/6; 44 15.47 (11.20)/4; 48 Group = 0.00
Allele status= 0.65
Interaction = 0.17
BITE symptoms1 6.30 (4.47)/1; 15 9.87 (6.77)/0; 24 2.83 (3.37)/0; 8 2.69 (2.82)/0; 12 Group = 17.75***
Allele status = 1.29
Interaction = 1.09
0.06484
3FEQ Dietary
restraint1
13.55 (4.19)/8; 21 13.65 (4.06)/6; 23 10.08 (3.69)/6; 16 10.80 (3.69)/5; 18 Group = 8.93**
Allele status = 0.15
Interaction = 0.28
0.00937
3FEQ
Disinhibition1
18.20 (4.15)/12; 25 21.56 (7.50)/10; 36 12.66 (2.33)/10; 15 13.72 (4.31)/8; 25 Group = 20.66***
Allele status = 1.99
Interaction = 0.275
0.02075
3FEQ Hunger1 6.60 (2.67) 3; 10 7.75 (2.55) 3; 12 4.50 (1.51) 3; 7 4.86 (2.49) 3; 12 Group = 15.22***
Allele status= 0.96
Interaction = 0.04
0.02149
Results are controlled for gender and depression scores.
1raw score.
SD = Standard deviation; LN = Letters and Numbers (WAIS III); SDMT = Symbol Digit Modalities Test; TMT = Trail making Test; WCST = Wisconsin Card Sorting Test;
BITE = Bulimic lnvestigatory Test Edinburgh; 3FEQ = 3-factor Eating Questionnaire.
*p,0.05; **p,0.01; ***p,0.001; Ef S = effect size: 2 = 0.0099, small effect; 2 = 0.0588, medium effect; 2 = 0.1379, large effect.
doi:10.1371/journal.pone.0041482.t008
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Results
Comparisons between obese and control subjects in demo-
graphics, neuropsychological and questionnaire scores are shown
in table 3.
Frequencies of DRD2/ANKK1-TaqIA alleles and genotypes,
and the frequencies of DRD4 VNTR alleles and genotypes in
obese and control subjects are shown in table 4 and table 5
respectively. As can be seen in Table 6 the frequency of allele
carriers and non-carriers did not differ between obese and control
participants for either of the two genotypes.
Although age, education and estimated intelligence were
equivalent for all genetic subgroups, the DRD4-7R carriers group
contained significantly more females than did the group compris-
ing non-carriers of 7R (DRD2/ANKK1-TaqIA subgroups: age:
F = 0.02; p = 0.872; years of education: F = 1.15; p = 0.286;
vocabulary (WAIS): F = 0.15; p = 0.693; sex: U = 584; p = 0.47;
DRD4-7R subgroups: age: F = 0.02; p = 0.869; years of education:
F = 0.00; p = 0.950; vocabulary (WAIS): F = 0.50; p = 0.479; sex:
U = 390; p = 0.032). Therefore, to rule out the effect of sex on the
DRD4 7R allele comparisons we introduced additionally this
variable in the ANCOVA analysis.
Table 7 shows the effect of ‘group’, ‘DRD2/ANKK1-TaqIA
A1-allele status’ and their interaction on executive functions and
eating behaviour variables controlled for depression. No significant
‘group’ effects were observed for any of the executive variables.
However, there was a significant main effect of ‘allele status’ on
LN SDMT, TMT B, and the number of perseverative errors on
the WCST. Subjects bearing the A1 allele performed worse than
those non A1-carriers subjects. There was also a significant ‘group’
x ‘DRD2/ANKK1-TaqIA A1-allele status’ interaction effect on
the LN score (Figure 1).
As expected, there was a significant ‘group’ effect on all the
eating behaviour variables. Interestingly, however, the results also
revealed a significant effect of ‘allele status’ on two of these
variables (BITE symptoms and the disinhibition subscale of the
3FEQ), as well as a significant ‘group’ x ‘DRD2/ANKK1-TaqIA
A1-allele status’ interaction effect on BITE symptoms (Figure 2).
Table 8 shows the effect of ‘group’, ‘DRD4 VNTR 7R-allele
status’ and their interaction on executive functions and eating
behaviour controlled for gender and depression scores. No
significant main effects of ‘group’ or ‘allele status’ were observed
for any of the executive variables. However, there was a significant
‘group’ x ‘DRD4 VNTR 7R- allele status’ interaction effect on
TMT B and TMT B-A scores (Figure 3). Eating behaviour
variables these were all subject to a significant main effect of
‘group’.
Discussion
The purpose of this study was to examine the association
between two dopamine genes and executive function and their
potential interactions with obesity. Specifically, the two dopamine
system genes chosen were the DRD2/ANKK1-TaqIA and DRD4
48 bp VNTR polymorphisms. Both have been associated with
psychiatric disorders involving impulsivity and obesity. In addi-
tion, these polymorphisms appear to exert a functional influence
on dopamine D2 and D4 receptors, which are densely located in
the corticostriatal-mesolimbic system [10–13,73,74], and they
could potentially affect performance of frontal functions via
Figure 3. ‘Group’ x ‘DRD4 VNTR 7R- allele status’ interaction effect on TMT B-A score. Performance in TMT B-A is obtained by regressing
depression and gender on the dependent variable, and then saving the standardized residual from this model.
doi:10.1371/journal.pone.0041482.g003
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frontosubcortical circuits linking the frontal cortex to distinct areas
of the striatum [75,76].
Previous studies have demonstrated altered executive function
in obese subjects [77–79]. By contrast, we found no relationship
between obesity and worse performance on executive function
variables, there being no significant effect of ‘group’ on any of the
executive variables analysed. Conversely, the A1 allele of the
DRD2/ANKK1-TaqIA polymorphism was clearly associated
with poor performance on executive tasks in both obese and
control subjects. Specifically, significant differences between the
two ‘allele status’ groups were observed for four of the seven
executive variables analysed, with A1 allele carriers performing
worse than A1 non-carriers.
Studies of frontal function and the DRD2/ANKK1-TaqIA
polymorphism in healthy adult samples have yielded conflicting
results. Some recent investigations have revealed carriers of the A1
allele to have better cognitive flexibility than A1 non-carriers
[33,34]. By contrast, other authors have shown that A1 carriers
are less efficient at learning to avoid actions that have negative
consequences [36] and that they have difficulty in learning from
negative feedback in a reinforcement learning task [35]. Our A1
allele carriers (including both obese and control subjects) showed
worse performance on variables involving motor speed, verbal and
visuo-spatial working memory, set-shifting, attention and tracking,
and cognitive flexibility. These results are therefore in line with
those studies that have shown greater difficulty in performing tasks
involving executive functions in subjects carrying the A1 allele,
regardless of the test/task used [35,36].
Our results also revealed a significantly ‘group’ x ‘DRD2/
ANKK1-TaqIA A1-allele status’ interaction effect on the LN
variable. In the obese group, A1 carriers performed worse than did
A1 non-carriers, whereas among controls the performance of A1
carriers and non-carriers was similar. This suggests that possession
of the A1 allele among obese subjects is associated with worse
performance on working memory, and it could therefore confer a
disadvantage in terms of executive performance. Other studies
with pathological samples involving the dopaminergic system have
yielded discordant results regarding frontal function. In a sample
of alcoholic males those subjects bearing at least one copy of the
A1 allele showed lower attention and less inhibitory control than
did those without the A1 allele [80], whereas Bombin et al. [81], in
a sample of psychotic adolescents, failed to detect an effect of the
DRD2/ANKK1-TaqIA polymorphism on executive functions.
The A1 allele of the DRD2/ANKK1-TaqIA gene has been
associated with addictive disorders [18–20]. Significant associa-
tions between the A1 allele of the DRD2/ANKK1-TaqIA
polymorphism and variables that indicate pathological food intake
were found in our sample. Subjects carrying the A1 allele scored
higher on the BITE scale and on the disinhibition subscale of the
3FEQ, implying greater overconsumption of foods associated with
a loss of control over food intake. We also found a significant
interaction between ‘group’ and ‘DRD2/ANKK1-TaqIA A1-
allele status’ in relation to BITE symptoms. In the obese group,
carriers of the A1 allele scored significantly higher on the BITE
than did A1 non-carriers. These results were expected since food
reinforcement and impulsivity have been reported to be greater in
obese individuals with the A1 allele [48,82].
No significant ‘group’ or ‘DRD4 VNTR 7R-allele status’ effects
were observed for any of the executive variables analysed. In this
regard, our data partially support the results of previous studies
that found no differences among ADHD patients in relation to the
DRD4 VNTR polymorphism and cognitive functions
[44,51,53,56]. Interestingly, however, we did find a significant
‘group’ x ‘DRD4 VNTR 7R-allele status’ interaction effect on
TMT B and TMT B-A scores. Specifically, in the obese group the
performance of 7R carriers was worse than that of 7R non-
carriers, whereas among controls the performance of 7R carriers
was better than that of non-carriers. These results are consistent
with previous studies that have reported associations between
being a carrier of 7R and impairment on executive function tasks
in healthy children [50], adults [54] and in children with ADHD
[50–52]; they also support the findings of those authors who have
reported better performance among subjects with the DRD4 long
(6–8) repeats compared to the DRD4 short (2–5) repeats [53]. It
would seem, therefore, that obesity is a key factor in relation to
possession of the allele. Being obese and having the DRD4 7-
repeat allele appears to confer a weakness in terms of the
performance of executive functions.
At all events the strengths and limitations of the present study
should be considered when interpreting the findings. The study
sample size was modest, and research designed to identify genes
that are associated with specific behaviours usually requires a
much larger sample. Nevertheless, this sample size did provide
enough statistical power to detect a significant interaction and
main effect of gene variants on our measures of executive function,
even though the effect sizes were small. The results should,
however, be interpreted with caution in view of the numerous
statistical comparisons, the risk being that some of the findings
may be spurious. The present results therefore require confirma-
tion by studies that are adequately powered to detect the effect of
DRD2-A1 and DRD4-7R on executive performance.
Ideally one would also have investigated all possible interactions
among the two polymorphisms studied here. However, for the
DRD4 48-bp VNTR and the DRD2/ANKK1-TaqIA polymor-
phisms the genotype frequencies involving the minor allele were
too low to test for meaningful interactions. Future studies should
therefore address the question of all potential interactions between
these two (and other) polymorphisms in dopamine system genes in
a larger, adult, obese cohort.
To conclude, despite the methodological limitations, we found
that obese subjects carriers of the A1 allele of the DRD2/ANKK1
TaqA1 and carriers of the 7R allele of the DRD4 48-bp VNTR
polymorphism performed worse on certain tests of executive
functions. These results provided new knowledge on the effect of
two genes that are crucial for dopamine neurotransmission, which
underlies several psychiatric disorders. The study of the genes
related to dopamine transmission, with respect to both its
elimination and its release or receptor binding, may shed light
on the role of this system in mental disorders.
Supporting Information
Figure S1 The figure shows detailed information on
data inclusion.
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